Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (365)	10/21/1998 8:52:00 AM
From: Danny Hayden	Respond to of 642

Prozac helps Eli Lilly Sales of anti-depressant drug helps pharmaceutical firm boost 3Q profits October 21, 1998: 8:30 a.m. ET Prozac cheers up Eli Lilly - July 22, 1998 Eli Lilly CEO to retire - May 6, 1998 Eli Lilly NEW YORK (CNNfn) - Higher sales of its top-selling drug Prozac helped Eli Lilly & Co. post a 13.4-percent rise in third-quarter earnings, which included a pretax charge for research and development costs. The Indianapolis, Ind.-based pharmaceutical company reported net income of $518.2 million, or 46 cents a share, compared with $456.9 million, or 40 cents a share, a year ago. Included in the latest results is a charge of $127.5 million for acquired technology. The expense reduced profit by 7 cents a share, meaning earnings from operations actually totaled 53 cents. Analysts were anticipating Eli Lilly to post profits of 51 cents a share. Shares of Eli Lilly (LLY) rose 5/16 on Tuesday to 75-3/8. Total revenue rose 19 percent to $2.57 billion helped by a 12-percent increase in sales of Prozac, which amounted to $793 million. The anti-depression treatment recorded better sales in the United States than overseas, where sales were essentially flat. For the first nine months of the year, operating profit totaled $1.5 billion, or $1.37 a share, on sales of $7.2 billion.

To: Henry Niman who wrote (365)	10/21/1998 2:59:00 PM
From: Anthony Wong	Read Replies (2) \| Respond to of 642

Lilly CFO Sees 1998 EPS at $1.93 to $1.94, 1999 at $2.25-$2.30 Bloomberg News October 21, 1998, 12:58 p.m. ET Lilly CFO Sees 1998 EPS at $1.93 to $1.94, 1999 at $2.25-$2.30 Indianapolis, Oct. 21 (Bloomberg) -- Eli Lilly & Co. could have 1998 per-share earnings of $1.93 to $1.94 and 1999 per-share earnings of $2.25 to $2.30, said Charles Golden, the company's chief financial officer. Lilly had been expected to earn $1.93 a share in 1998 and $2.28 a share in 1999, the average estimates of analysts polled by First Call Corp. Golden said the company was not guiding analysts to a higher estimate of $1.95 a share for 1998 profit. Golden's comments were made during a conference call after Lilly reported a 30 percent increase in third-quarter profit. Profit before a charge for the world's 10th-largest drugmaker rose to $595 million, or 53 cents a share, from net income of $456.9 million, or 40 cents, a year earlier. Sales rose 19 percent to $2.57 billion from $2.16 billion. A charge of $76.8 million, or 7 cents a share, for a payment to Icos Corp. for their impotence-pill collaboration, resulted in net income of $518.2 million, or 46 cents. --Kerry Dooley in the Princeton newsroom (609) 279-4016/gfh